SeaStar Medical Holding Corporation announced that Chief Executive Officer Eric Schlorff will present at the Virtual Investor Summit Conference on June 24, 2026, at 10:30 am Eastern Time. The presentation aims to provide investors with insights into the company's operations and strategic direction. Interested investors can register to view the live presentation through the official SeaStar Medical Events portal.

A replay of the presentation will be made available on the company's website and can be accessed shortly after the event concludes. The replay will remain accessible for up to 30 days following its posting, allowing stakeholders to review the content at their convenience.

About SeaStar Medical

SeaStar Medical is a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and potential loss of life. The company's first commercial product, QUELIMMUNE (SCD-PED), was approved in 2024 by the U.S. Food and Drug Administration (FDA). It is the only FDA-approved product for the ultra-rare condition of life-threatening Acute Kidney Injury (AKI) due to sepsis or a septic condition requiring renal replacement therapy (RRT) in critically ill pediatric patients.

The company's Selective Cytopheretic Device (SCD) therapy has been awarded Breakthrough Device Designation for six therapeutic indications by the FDA. This designation enables a potential speedier pathway to approval and preferable reimbursement dynamics at commercial launch. SeaStar Medical is currently conducting the NEUTRALIZE-AKI pivotal clinical trial of its SCD therapy in adult patients with AKI requiring continuous renal replacement therapy, a life-threatening condition with no effective treatment options that impacts over 200,000 adults in the U.S. annually.